文献速递脑血管病

妊娠期缺血性卒中溶栓治疗的母亲与胎儿安全结局:系统综述与聚合病例系列

Maternal and Fetal Safety Outcomes of Thrombolytics for Ischemic Stroke in Pregnancy: A Systematic Review and Aggregated Case Series.
PubMed 文献 · Neurology · 2026-10-30

贝叶斯聚合病例系列分析显示,溶栓人群流产风险较普通孕妇高12.4%(95%CrI 2.6%–23.2%),死产风险高5.9%(95%CrI 1.6%–12.7%);症状性颅内出血比例与年轻非妊娠溶栓患者相似(风险差-0.4%,95%CrI -0.8%–2.7%)。

要点

  • 妊娠期溶栓后流产风险较普通孕妇高12.4%,死产风险高5.9%
  • 症状性颅内出血风险与年轻非妊娠溶栓患者无显著差异
  • 32例胎儿死亡中仅6例可能与溶栓因果相关(卒中3例)

核心结论

  • 溶栓治疗可能与少数已发表的妊娠期溶栓后胎儿死亡病例存在因果关联,但未发现对母亲有害的信号,包括症状性颅内出血率相似。
  • 研究结果总体支持对符合条件的妊娠患者使用溶栓治疗,但强调需进行风险获益评估。

研究设计与样本

  • 纳入123项研究共216例妊娠期接受溶栓治疗的患者(中位年龄31岁),其中85例为缺血性卒中;另纳入深静脉血栓、机械瓣血栓和肺栓塞的妊娠期溶栓病例以补充安全性数据。
  • 采用贝叶斯聚合病例系列分析,将本队列不良结局发生率与普通人群进行比较。
  • 研究方案已在PROSPERO预注册(CRD42024605043)。

主要发现

  • 216例妊娠期溶栓患者中,32例胎儿死亡,其中6例被认为可能与溶栓因果相关(卒中病例中3例)。
  • 溶栓人群流产风险较已发表的普通孕妇人群高12.4%(95%CrI 2.6%–23.2%)。
  • 溶栓人群死产风险较普通孕妇人群高5.9%(95%CrI 1.6%–12.7%)。
  • 妊娠队列与年轻非妊娠溶栓患者相比,症状性颅内出血比例相似(风险差-0.4%;95%CrI -0.8%–2.7%)。

关键数值与推荐

  • 流产风险差异:+12.4%(95%CrI 2.6%–23.2%),对象为妊娠期溶栓患者 vs 已发表普通孕妇人群。
  • 死产风险差异:+5.9%(95%CrI 1.6%–12.7%),对象为妊娠期溶栓患者 vs 已发表普通孕妇人群。
  • 症状性颅内出血风险差:-0.4%(95%CrI -0.8%–2.7%),对象为妊娠溶栓队列 vs 年轻非妊娠溶栓患者。
  • 胎儿死亡与溶栓因果相关:6/32例(卒中病例中3例)。

临床怎么用

  • 对于其他方面符合条件的妊娠期缺血性卒中患者,溶栓治疗总体可接受,但需个体化评估风险获益。
  • 咨询时应告知流产和死产风险较普通孕妇略有升高,但母亲症状性颅内出血风险未见增加。
  • 胎儿结局受疾病本身影响难以与溶栓效应区分,决策需结合多学科评估。

局限性

  • 许多病例中难以区分溶栓对胎儿结局的影响与疾病本身的影响,结果需谨慎解读。
  • elective termination与自然流产被合并分组,因常难以判断溶栓并发症是否影响终止妊娠决策。
  • 证据基于已发表病例的聚合分析,可能存在发表偏倚和报告不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The safety of intravenous thrombolytics for ischemic stroke in pregnancy is largely unknown. We performed a systematic review to identify published use of thrombolytics for stroke during pregnancy, with the aim of assessing maternal and fetal safety outcomes. To provide additional safety data, we included cases of thrombolysis for deep vein thrombosis, mechanical valve thrombosis, and pulmonary embolism in pregnancy. METHODS: We used the PRISMA and MOOSE guidelines to conduct the review. We searched 3 databases (OVID Medline, EMBASE, Scopus) for studies published up to October 2025. We analyzed outcomes in a Bayesian aggregated case series to compare rates of adverse outcomes in our cohort with those in the general population. Elective termination and spontaneous abortion were grouped together, given that it was often difficult to determine whether complications of thrombolysis may have played a role in the decision for termination. RESULTS: We included 123 studies of 216 patients (median age 31 years) treated with thrombolytics during pregnancy, of whom 85 had ischemic stroke. Six of the 32 total fetal deaths were deemed likely to be causally related to thrombolytics (3 in stroke). The risk of miscarriage in our thrombolysis population was 12.4% higher (95% credible interval [CrI]: 2.6%, 23.2%) than published general pregnant population rates, and the risk of stillbirth was 5.9% higher (95% CrI: 1.6%, 12.7%). The proportion of pregnant patients with symptomatic intracerebral hemorrhage was similar between our pregnant cohort and young, nonpregnant patients receiving thrombolytics (risk difference -0.4%; 95% CrI: -0.8%, 2.7%). DISCUSSION: Thrombolytics were likely causally associated with a small minority of published cases of fetal death after thrombolysis in pregnancy. There was no signal of increased harm from thrombolysis to the mother, including similar rates of symptomatic intracerebral hemorrhage. In many cases, it was difficult to discern effects of thrombolytics on fetal outcomes from the effects of the disease itself; hence, our results should be interpreted with caution. Nonetheless, our findings broadly support the use of thrombolytics in otherwise-eligible pregnant patients but underscore the importance of the risk-benefit assessment in such patients. TRIAL REGISTRATION INFORMATION: The study protocol was pre-registered on PROSPERO (registration number: CRD42024605043).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Payne T, Liu D, Frawley T, et al. Maternal and Fetal Safety Outcomes of Thrombolytics for Ischemic Stroke in Pregnancy: A Systematic Review and Aggregated Case Series. Neurology. 2026. PMID: 42962168. doi:10.1212/WNL.0000000000218590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。